 After a magnificent performance last year with Caplyta approval for schizophrenia, Intra-Cellular stocks gave up some gains. And its been trading in cyclical growth spurts of gives and takes. Investors are eyeing Caplyta sales to ascertain that the drug has strong sales prospects. Moreover, they want to see additional catalysts materialize. 